Description: Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Home Page: www.sangamo.com
SGMO Technical Analysis
Brisbane,
CA
94005
United States
Phone:
510 970 6000
Officers
| Name | Title |
|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | CEO, Pres & Director |
| Ms. Prathyusha Duraibabu CPA, M.B.A. | Sr. VP, CFO & Principal Accounting Officer |
| Mr. D. Mark McClung | Exec. VP & COO |
| Dr. R. Andrew Ramelmeier Ph.D. | Exec. VP of Technical Operations |
| Dr. Jason D. Fontenot Ph.D. | Sr. VP & Chief Scientific Officer |
| Ms. Aron Feingold | Head of Corp. Communications & Investor Relations Officer |
| Mr. Scott B. Willoughby | Sr. VP, Gen. Counsel & Corp. Sec. |
| Ms. Whitney Jones | Sr. VP & Chief People Officer |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Chief Devel. Officer |
| Ms. Heather Erickson | Chief of Staff |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8288 |
| Price-to-Sales TTM: | 4.8262 |
| IPO Date: | 2000-04-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 431 |